-
European, US stocks back in sell-off mode as oil prices surge
-
Pete Hegseth: Trump's Iran war attack dog
-
Celtics' Tatum could make injury return on Friday
-
'Enemy at home': Iranian authorities tighten grip as war rages
-
Bethell set for 'hell of a career', says England captain Brook
-
France coach Galthie slams Scotland for 'smallest changing room in the world'
-
Medvedev arrives in Indian Wells after being stranded in Dubai
-
Trump fires homeland security chief Kristi Noem
-
Mideast war risks pulling more in as conflict boils over
-
Wales' James Botham 'sledged' by grandfather Ian Botham after Six Nations error
-
India hero Samson eyes 'one more' big knock in T20 World Cup final
-
Britney Spears detained on suspicion of driving while intoxicated
-
Grooming makes Crufts debut as UK dog show widens offer
-
Townsend insists Scots' focus solely on France not Six Nations title race
-
UK sends more fighter jets to Gulf: PM
-
EU to ban plant-based 'bacon' but veggie 'burgers' survive chop
-
Leagues Cup to hold matches in Mexico for first time
-
India reach T20 World Cup final after England fail in epic chase
-
Conservative Anglicans press opposition to Church's first woman leader
-
Iran players sing anthem and salute at Women's Asian Cup
-
India beat England in high-scoring T20 World Cup semi-final
-
Mideast war traps 20,000 seafarers, 15,000 cruise passengers in Gulf
-
Italy bring back Brex to face England
-
French policeman to be tried over 2023 killing of teen
-
Oil prices rise, stocks slide as Middle East war stirs supply concerns
-
More flights take off despite continued fighting in Middle East
-
Ukraine, Russia free 200 POWs each
-
Middle East war halts work at WHO's Dubai emergency hub
-
Paramount's Ellison vows CNN editorial independence
-
US says attacks on alleged drug boats have spooked traffickers
-
Dempsey returns as Scotland shuffle pack for Six Nations clash against France
-
India pile up 253-7 against England in T20 World Cup semi-final
-
Wary Europeans pledge 'defensive' military aid in Mideast war
-
Seven countries to boycott Paralympics ceremony over Russia: organisers
-
UK's Crufts dog show opens with growing global appeal
-
PSG prepare for Chelsea clash with Monaco rematch
-
Google opens AI centre as Berlin defends US tech reliance
-
Second Iranian ship nears Sri Lanka after submarine attack
-
Portugal mourns acclaimed writer Antonio Lobo Antunes
-
Union loses fight against Tesla at German factory
-
Wales revel in being the underdogs, says skipper Lake
-
German school students rally against army recruitment drive
-
Wary European states pledge military aid for Cyprus, Gulf
-
Liverpool injuries frustrating Slot in tough season
-
Real Madrid will 'keep fighting' in title race, vows Arbeloa
-
Australia join South Korea in quarters of Women's Asian Cup
-
Kane to miss Bayern game against Gladbach with calf knock
-
Henman says Raducanu needs more physicality to rise up rankings
-
France recall fit-again Jalibert to face Scotland
-
Harry Styles fans head in one direction: to star's home village
Brazilian ritual root gets second life as potential anti-depressant
Long used in Indigenous Brazilian rituals, the jurema preta plant, which contains a potent psychedelic, is gaining ground as a potential treatment for depression.
At street stalls where medicinal herbs are sold, customers can buy the plant's root which contains dimethyltryptamine (DMT), a hallucinogenic substance that researchers say could be used to alleviate symptoms.
Following instructions he found on the internet, Guaracy Carvajal extracted DMT at home in 2016 from roots he bought on the street.
The 31-year-old software programmer, who had tried various treatment for chronic depression he has suffered since adolescence, said the drug makes it "feel like you've solved something in your life."
Physicist Draulio Araujo, who has conducted extensive research on the drug, said "the response is rapid. One day after treatment, (patients) already showed a significant improvement in their depression symptoms."
Yet he also warned that it "is not a magic cure" and that psychedelics "are not for everyone."
As a researcher at the Brain Institute of the Federal University of Rio Grande do Norte, Araujo and his team treated 14 people with the drug for six months.
The patients inhaled vaporized DMT, under medical supervision.
"It's common for our patients to say that something changed, that a key opened something," he said.
His patients also received psychological therapy, and some continued with conventional pharmaceutical drugs.
Neuroscientist Fernanda Palhano-Fontes, also of the Brain Institute, said "we have patients who improve significantly, others who don't improve at all."
Araujo's findings were published in the scientific journal Nature in April. In 2024, he published another study with promising results in the journal Psychedelic Medicine.
As for Carvajal, who stopped using jurema preta some time ago, he said the drug really allows a person to "start to have a lighter life."
It helped him get through a time when he was in "a state of questioning myself" about "work, day-to-day life," he said.
- Spiritual channels -
Brazil occupies a fairly prominent place in DMT research due to the substance's prominence in society, Araujo said.
While there is no ban on the cultivation or possession of jurema, which is also known as Mimosa tenuiflora, consumption of DMT is prohibited, except for religious and scientific use.
Jurema's roots are combined with other plants in a wine-like beverage that is consumed at rituals that include dancing and drums, part of Indigenous tradition in northeast Brazil where the plant grows.
"It's not hallucination," said Joyce Souza, a young woman attending a jurema ceremony in Planaltina, on the outskirts of Brasília.
"My spiritual channels become more accessible, I can communicate better with myself," Souza said.
Gathered in a house courtyard and dressed in white, the group of mostly novices waited for more seasoned practitioners to enter a trance and bring messages from ancient spirits.
Meanwhile, back in the lab, Araujo is hoping to expand his DMT research to a study of 100 patents.
"Let's say that in five years we'll have... a clear picture on when it will reach a real clinical setting," he said.
S.Gantenbein--VB